IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Dec. 30, 2019– Urovant Sciences (Nasdaq: UROV) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug…Original Article
Urovant Sciences Announces Submission of New Drug Application for Vibegron for the Treatment of Overactive Bladder
